UBX0101

Phase 1Completed

2 views this week 0 watching💤 Quiet

Interest: 19/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Knee Osteoarthritis

Conditions

Knee Osteoarthritis

Trial Timeline

Jan 23, 2020 → Sep 18, 2020

NCT ID

NCT04229225

About UBX0101

UBX0101 is a phase 1 stage product being developed by Unity Biotechnology for Knee Osteoarthritis. The current trial status is completed. This product is registered under clinical trial identifier NCT04229225. Target conditions include Knee Osteoarthritis.

What happened to similar drugs?

8 of 20 similar drugs in Knee Osteoarthritis were approved

Approved (8) Terminated (0) Active (12)

✅NISEDr. Reddy's LaboratoriesApproved

✅Capsaicin Topical SolutionAstellas PharmaApproved

🔄Duloxetine + PlaceboShionogiPhase 3

🔄DuloxetineShionogiPhase 3

🔄Duloxetine + PlaceboEli LillyPhase 3

🔄Duloxetine (DLX) + Placebo (PLA)Eli LillyPhase 3

🔄Duloxetine + placeboEli LillyPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04229225	Phase 1	Completed	Jan 23, 2020	Sep 18, 2020	Knee Osteoarthritis
NCT04129944	Phase 2	Completed	Oct 30, 2019	Aug 7, 2020	Osteoarthritis, Knee
NCT03513016	Phase 1	Completed	May 16, 2018	Apr 12, 2019	Osteoarthritis, Knee

Competing Products

20 competing products in Knee Osteoarthritis

See all competitors

Product	Company	Stage	Hype Score
NISE	Dr. Reddy's Laboratories	Approved	40
NISELAT	Dr. Reddy's Laboratories	Pre-clinical	23
LY2828360 + Placebo	Eli Lilly	Phase 2	35
UBX0101 or placebo	Unity Biotechnology	Pre-clinical	8
UBX0101	Unity Biotechnology	Phase 2	25
UBX0101	Unity Biotechnology	Phase 1	19
YH23537 + Celecoxib + YH23537 placebo	Yuhan	Phase 2	35
YM150 + Warfarin	Astellas Pharma	Phase 2	35
ASP7962 + Naproxen + Placebo	Astellas Pharma	Phase 2	35
Capsaicin Topical Solution	Astellas Pharma	Approved	43
CGS-200-1 + CGS-200-5 + CGS-200 Vehicle	Astellas Pharma	Phase 2	35
MM-II dose I + MM-II dose II + MM-II dose III + Placebo + Placebo + Placebo	Sun Pharmaceutical	Phase 2	35
Duloxetine + Placebo	Shionogi	Phase 3	40
Duloxetine	Shionogi	Phase 3	40
V120083 + Naproxen + Placebo	Shionogi	Phase 2	35
ONO-4474 + Placebo matching ONO-4474	Ono Pharmaceutical	Phase 2	27
Duloxetine + Placebo	Eli Lilly	Phase 3	40
Duloxetine (DLX) + Placebo (PLA)	Eli Lilly	Phase 3	40
Duloxetine + placebo	Eli Lilly	Phase 3	40
Placebo + LY545694 49 mg + LY545694 105 mg	Eli Lilly	Phase 2	35